Screener
Cytek Biosciences, Inc. CTKB Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| (In thousands, except share and per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued expenses | 23,855 | 23,417 |
| Other current liabilities | 20,513 | 16,978 |
| Deferred revenue, current | 29,206 | 28,504 |
| Total current liabilities | 84,335 | 77,804 |
| Legal settlement liability, noncurrent | 6,368 | 6,786 |
| Deferred revenue, noncurrent | 18,058 | 18,339 |
| Operating lease liability, noncurrent | 13,517 | 14,042 |
| Long-term debt | 246 | 525 |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s total current liabilities?
- Cytek Biosciences, Inc. (CTKB) reported total current liabilities of $84.34M in Q2 2026.
- How has Cytek Biosciences, Inc.'s total current liabilities changed year-over-year?
- Cytek Biosciences, Inc.'s total current liabilities increased by 15.1% year-over-year, from $73.27M to $84.34M.
- What is the long-term trend for Cytek Biosciences, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s total current liabilities has grown at a 24.0% compound annual growth rate (CAGR), from $26.54M to $77.8M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Cytek Biosciences, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude